THE CURRENT CHALLENGE OF HCV-RNA RESISTANCE AGAINST DIRECT-ACTING ANTIVIRAL DRUGS.
Nida Taha, Bashir Ahmad
1. M.Phil (Pharmacology) Scholar, Riphah Institute of Pharmaceutical Sciences, Ripah International University Lahore, Pakistan.
2. Professor of Pharmacology, Riphah Institute of Pharmaceutical Sciences, Ripah International University Lahore, Pakistan.
Keywords: HCV-RNA, Resistance, Direct-Acting Antiviral.
The HCV-RNA (Hepatitis-C RNA) diagnosed patients are recommended interferon free Direct-Acting Antiviral (DAAs) therapy. Although the treated patients are reported viral resistance to DAAs, the genotype 3a infection is challenge to NS5A inhibitors leading to cirrhosis. Therefore, the patients with chronic Hepatitis-C treated with DAAs, nucleotide analogue inhibitors or NS5B protein have high risk of resistance. Breakthrough or relapse is not common with these drugs when used as monotherapy.NS3-4A protease inhibitors and non-nucleoside inhibitors have low susceptibility to resistance. Sofosbuvir-resistant variants have been discovered that disappear after treatment withdrawal. Patients who experience relapse after an INF-free treatment have large fraction of drug resistant viruses.
© 2016 The Author(s). This open access article is distributed under a Creative Commons Attribution (CC-BY) 4.0 license.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made.
You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits